CCW702 is an investigational immunotherapy for metastatic castration
resistant prostate cancer being developed by Calibr in a
first-in-patient clinical trial. AbbVie holds an option to license the
program at the conclusion of the trial.
Type of MoleculeBiologic
Product TypeNew Indication
|Potential Indication||Region||Phase (1, 2, 3, Submitted)|